Clinical Trial

Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria

Study acronym: RICHH
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2017-09-29; most recent amendment 2026-06-18.
Status change: Not Yet Recruiting → Recruiting 2018-06-19
Trial Details
NCT Number NCT03301038
Lead Sponsor Children's Hospital of Philadelphia
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease, Hypercalcemia, Idiopathic, of Infancy, Hypercalciuric Hypercalcemia, Idiopathic Infantile Hypercalcemia - Mild Form, Hypercalciuria
Enrollment 60 participants
Start Date 2018-07-25
Primary Completion 2027-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-22